ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approvals: Cobas HPV Test Approved For Primary Cervical Screening

April 25, 2014

In Brief: Vicent Bono Retires As Investigational Drugs Branch Chief; Weiss to Leave For Walter Reed

January 9, 1981

Review Of NCI Intramural Program Offers Over 60 Recommendations For Change

July 7, 1995

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

September 28, 2012

NIH To Site Visit Animal Facilities

March 18, 1983

Book Related History Of Cancer Act

March 3, 1978